Agios is a biopharmaceutical company that sells mitapivat and develops other medicines for rare diseases, mainly blood disorders. AGIO reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in AGIO, 0% of them bullish and 100% bearish.
Prices, price targets and earnings estimates for AGIO are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
Each firm's latest rating on AGIO in the past 90 days
Average 12-month target
Price targets for AGIOThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plansSign in
Latest rating changes
HC Wainwright & Co.Assumed coverage
Oct 29Buy
Truist SecuritiesTarget lowered
Oct 7Buy
B of A SecuritiesTarget raised
Sep 21Buy
JP MorganTarget raised
Aug 7Hold
CitigroupMaintained
Jul 31Buy
Date
Firm
Action
Rating
Price target
Oct 29
HC Wainwright & Co.
Assumed coverage
Buy
Oct 7
Truist Securities
Target lowered
Buy
Sep 21
B of A Securities
Target raised
Buy
Aug 7
JP Morgan
Target raised
Hold
Jul 31
Citigroup
Maintained
Buy
Loading…
Whale Options Flow
90D
No whale options trades in AGIO in the last 90 days.
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 20 – Oct 20
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AGIO is in one of them and how their past AGIO trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Agios Pharmaceuticals
Agios is a biopharmaceutical company that focuses on rare diseases, with a foundation in hematology, the study of blood disorders. Its lead medicine, mitapivat, is sold under the brand names AQVESME and PYRUKYND and is approved to treat anemia in adults with certain rare blood disorders. The company is also developing additional medicines for rare blood and metabolic conditions. Agios is based in Cambridge, Massachusetts, and serves patients and the clinicians who treat them.
